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Clinical Features of PCOS
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Abstract
Polycystic ovary syndrome (PCOS) is a widespread pathology that affects 
multiple aspects of the general health of women, with long-term effects that go 
well beyond the reproductive age. The considerable variability of the clinical pre-
sentation, together with the lack of universally accepted diagnostic criteria, has so 
far contributed to making it difficult to identify a clear etiology of the disease. The 
exact etiology of PCOS is still not perfectly clear to date. It is therefore a multifac-
torial etiology, sharing of genetic and environmental factors. The contribution of 
genetics to the pathogenesis of PCOS is not due to a single gene but inheritance of 
gene clusters. The term “polycystic ovary syndrome” does not completely reflect 
the complexity of this syndrome which manifests a wide spectrum of clinical 
manifestations and comorbidity and important metabolic implications. PCOS 
patients showed an increase risk of developing type 2 diabetes mellitus, dyslipi-
daemia, endometrial cancer and cardiovascular diseases. The clinical aspects of 
PCOS are hyperandrogenism, oligomenorrhoea and ultrasound morphology of the 
ovary. The identification of the different manifestations of PCOS in the various 
phases of life, can, of course, help to organize individual therapeutic strategies 
and likely to prevent long-term metabolic consequences. The therapeutic choices 
will be based on the type and extent of the disorders and if there is a desire for 
pregnancy.
Keywords: polycystic ovary syndrome, hyperandrogenism, ultrasound, insulin, 
insulin resistance, metformin, hyperinsulinaemia, inositol, infertility,  
menstrual irregularities, anovulation, obesity
1. Introduction
Polycystic ovary syndrome (PCOS) was first observed by Stein and Leventhal 
who in 1935 described seven women with amenorrhoea, hirsutism and increased 
volume of the ovaries characterized by the presence of numerous cysts [1]. The 
exact etiology of PCOS is still not perfectly clear to date. It is therefore a multifacto-
rial etiology, sharing of genetic and environmental factors [2]. The contribution 
of genetics to the pathogenesis of PCOS is not due to a single gene but inheritance 
of gene clusters [3]. The metabolic dysfunction in PCOS patients mainly reflects 
molecular dysfunction of insulin signaling pathway, mainly at the level of the skel-
etal muscle and of the adipose tissue. These defects seem to be partly intrinsic and 
partly acquired because of hormonal and metabolic situation. Androgens, bioactive 
mediators (adipokines) and other pro-inflammatory molecules contribute to the 
altered action of insulin on peripheral tissues.
Insulin acts as a regulator of glucose balance by stimulating the uptake of glucose 
from insulin-sensitive tissues, such as adipose tissue and skeletal and cardiac 
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muscle, and suppressing hepatic glucose production. Insulin is also able to suppress 
lipolysis leading to a decrease in free fatty acid levels (FFAs), which can mediate the 
action of insulin on the hepatic production of glucose. Insulin resistance is defined 
as a decreased ability of insulin to carry out these metabolic actions inherent in the 
uptake of glucose, the production of glucose and lipolysis, which then leads to the 
need for more circulating insulin to maintain the same effects. Thus insulin resis-
tance is characterized by increased circulating levels of insulin, both basal and after 
loading glucose, if pancreatic function is normal [4].
2. Clinical aspects of PCOS
A biochemical and clinical hyperandrogenism of ovarian origin and to a 
lesser extent adrenal is evident in about 60–80% of PCOS patients, resulting 
in one of the main features of the syndrome [5]. Ovarian hyperandrogenism is 
mainly due to a defect in the intrinsic steroid synthesis in ovarian thecal cells. 
Extra-ovarian factors, such as high levels of LH and insulin and low levels of 
FSH, and intraovarian factors, such as anti-Müllerian hormone (AMH) and 
inhibin, may enhance the hyperandrogenism state. Also high levels of andro-
gens are recognized as one of the possible causes of PCOS insulin resistance. 
An excess of androgens during intrauterine life and in the immediate post-
natal period may lead to accentuate visceral adiposity and insulin resistance. 
Medications with anti-androgenic activity may improve insulin resistance. 
Androgens by acting directly on the insulin signaling system may contribute to 
the peripheral insulin resistance in patients with PCOS. Insulin resistance and 
compensatory hyperinsulinaemia are involved in all three main clinical aspects 
of the syndrome: hyperandrogenaemia, ovarian dysfunction and metabolic 
alterations [6].
The increased pulsatility of the LH leads to increased circulating LH levels that 
stimulate the ovarian cortex synthesis of androgens. Increased levels of LH are 
partly due to an altered negative feedback exerted by androgens on the hypotha-
lamic–pituitary axis [8]. Insulin, in synergy with LH, will enhance the stimula-
tion of androgen production by theca cells of the ovary and to a lesser extent the 
adrenal cortex. Insulin is also involved in the ovarian dysfunction by increasing 
the expression of LH receptors on the granulosa cells [9]. The first therapeutic 
approach in obese patients with PCOS is to achieve weight loss. In addition to an 
improvement of metabolic comorbidities associated with obesity, weight loss 
reduces hyperinsulinaemia with a consequent increase of insulin sensitivity, 
decreased LH and androgen levels and improvement of both menstrual cycle and 
fertility [10].
Patients with PCOS have an altered metabolism of inositol, and there is a con-
nection between insulin resistance and inositol deficiency [11]. In women with 
PCOS, at the level of muscle tissue, the conversion of myo-Inositol into D-chiro-
inositol is reduced due to a reduction in epimerasic activity. Furthermore, these 
patients show reduced serum D-chiro-inositol levels and an increase in urinary 
excretion of inositol phosphoglycan, which is inversely related to insulin sensi-
tivity, supporting the hypothesis according to which women with PCOS present 
a serious alteration of the metabolism of inositols, characterized by an excess of 
myo-inositol and a deficiency of D-chiro-inositol and a decrease in epimerasic 
activity. This hypothesis has led to focus the attention on the importance of 
myo-inositol and D-chiro-inositol supplementation to restore normal ovarian 
function [12].
3Clinical Features of PCOS
DOI: http://dx.doi.org/10.5772/intechopen.89961
3. PCOS and metabolic syndrome
The identification of the different manifestations of PCOS in the various phases 
of the life, can, of course, help to organize individual therapeutic strategies and 
likely to prevent long-term metabolic consequences. Women with PCOS may have 
different degrees of insulin resistance (IR) that contribute to the increased risk of 
metabolic syndrome. The latter, defined in the past as “syndrome X” or “insulin 
resistance syndrome” or “plurimetabolic syndrome”, is described by the association 
of various metabolic disorders, each of which is a known cardiovascular risk factor.
The definition of metabolic syndrome according to the National Cholesterol 
Education Expert Panel (NCEP) on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel III—ATPIII) provides for the 
presence of three or more disorders between:
1. Central obesity (waist circumference ≥88 cm).
2. Impaired glucose levels (fasting blood sugar ≥110 or ≥140 mg/dl after 2 hours 
after oral glucose test (OGTT)).
3. Arterial hypertension (PA ≥ 130/85).
4. Hypertriglyceridaemia (≥150 mg/dl).
5. Reduced HDL cholesterol (<50 mg/dl).
These criteria are most frequently used in scientific research [13].
The presence of obesity in women with PCOS results in the worsening of the 
clinical presentation, both from a metabolic and reproductive point of view [14]. 
Obese women with PCOS present:
1. Increased prevalence of impaired fasting glucose (IFG) and type 2 diabetes 
mellitus.
2. Higher prevalence of hirsutism (73% of obese vs. 56% of non-obese) [15].
3. Worst lipid profile.
4. Increased risk of metabolic syndrome and, therefore, cardiovascular diseases [16].
5. Higher prevalence of oligomenorrhoea, amenorrhoea and infertility [17].
6. Lower rate of ovulation and conception in response to clomiphene citrate. and 
to exogenous gonadotrophins, with need for higher doses.
7. Lower percentage of pregnancies in assisted reproduction techniques (IVF, 
ICSI) and increased frequency of spontaneous abortions [18].
It should be noted that a greater predisposition to the metabolic syndrome 
has been described throughout the body mass index (BMI) range, indicating that 
PCOS, independently of obesity, can confer an increased risk of developing this 
complication, due to the intrinsic insulin resistance that characterizes it. Women 
with PCOS and a combination of metabolic syndrome would exhibit greater insulin 
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resistance, higher levels of free testosterone, lower levels of SHBG and, phenotypi-
cally, greater frequency of acanthosis nigricans [16]. The prevalence of metabolic 
syndrome, however, would be higher in patients with high BMI than in those with 
normal BMI.
4. Pathophysiology
The considerable variability of the clinical presentation, together with the lack 
of universally accepted diagnostic criteria, has so far contributed to making it dif-
ficult to identify a clear etiology of the disease.
The three main endocrine changes of PCOS are:
1. Hyperandrogenism.
2. LH hypersecretion.
3. Hyperinsulinism.
The mechanisms by which these factors interact with each other in PCOS are 
extremely complex and not yet completely clarified [17].
The rapid onset of hyperandrogenism may be caused by steroid-secreting 
ovarian or adrenal tumors that must be ruled out in the differential diagnosis. On 
the contrary, the slow and progressive appearance of hyperandrogenism is often 
associated with medical history for a gradual increase in weight over time [19].
Several mechanisms that could determine Insulin resistance (IR) are:
• Excessive serine phosphorylation of the insulin receptor subunit.
• Mutations of the insulin receptor gene or IRS-1 (substrate of the insulin recep-
tor, phosphorylated by its tyrosine kinase activity, Tyr-K).
• Depletion of intracellular adenosine.
• Post-receptor defect of glucose transport.
• Impaired insulin clearance in peripheral tissues.
Obesity amplifies insulin resistance and hyperinsulin state in PCOS patients, 
and that, therefore, obese patients are more insulin-resistant and more hyper-
insulinaemic of the normal-weight counterpart. Despite the peripheral insulin 
resistance, ovarian tissue remains sensitive to action of insulin, probably because at 
this level, the transduction system involves a different second messenger, inositol 
phosphoglycan.
So, insulin can act directly on the cells of the ovary, activating cytochrome 
P450c17 and enhancing the synthesis of androgen induced by LH. The increased 
proactive androgenic action of insulin also manifests itself indirectly, by suppress-
ing the hepatic synthesis of sex hormone-binding globulin (SHBG) and insulin-
like grow factor-binding protein 1 (IGFBP-1), with consequent increase in the 
bioavailability of free testosterone of IGF-I. The latter would act by stimulating the 
secretion of progesterone and oestradiol and increasing the aromatase activity and 
production of androgens, respectively, in granulosa and thecal cells (Figure 1).
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Insulin acts by modifying the pulsatile secretion of GnRh increasing the sensi-
tivity of gonadotropic cells to GnRh.
An important role to the genesis of insulin resistance has been attributed to 
free fatty acids (FFA) [20]. The visceral adipocytes of women with PCOS have 
increased the lipolytic activity of abdominal fat with subsequent marked lipolytic 
activity that enhances the massive release of FFA in the portal blood. FFAs once 
they reach the liver trigger an inflammatory parenchymal state, induce a reduction 
in androgen clearance and inhibition of SHBG synthesis, but above all inhibit the 
hepatic extraction of circulating insulin. In this way FFA contribute to peripheral 
hyperinsulinaemia. FFA also compete with glucose as the energy substrate of 
skeletal muscles [21], and with this modality, they would contribute to the genesis 
of insulin resistance.
A contribution to hyperinsulinaemia also comes from a secretory pancreatic 
defect, found in some patients with PCOS even in the absence of glucose intoler-
ance or a frank type 2 diabetes [22]. In particular, an exaggerated pancreatic 
secretion was demonstrated in the first phase of the response to a hypoglycaemic 
stimulus administered in order to test pancreatic secretory capacity. This anomaly 
is present in lean PCOS as well as in obese PCOS resulting in a defect independent 
of other confounding factors such as BMI, adipose tissue distribution, peripheral 
sensitivity to insulin or a family history of noninsulin-dependent diabetes mel-
litus (NIDDM).
From the neuroendocrine point of view, PCOS represents distinctive feature of 
the inappropriate secretion of gonadotrophins. There are numerous studies that 
demonstrate the existence of an alteration of the hypothalamic–pituitary-ovary axis 
which is expressed on the hormonal level in:
• An increase in the secretion of LH: in particular, an increase in the amplitude 
and frequency of the LH observed in basal conditions [23].
• The relative suppression of FSH suggests that partial pituitary desensitization 
is secondary to the increased frequency of GnRH secretion [23].
An alteration of the circadian rhythm of LH is also observed with persistence 
of nocturnal hyperactivity typical of adolescence. This suggests the existence of a 
Figure 1. 
Insulin actions and androgen production [7].
Polycystic Ovarian Syndrome
6
marked hypersensitivity of the LH-secreting pituitary cells to the action of GnRH 
[24]. Another hypothesis suggests the presence of a partial loss of feedback control 
mechanisms on the hypothalamus that lead to a greater autonomy of the GnRH 
pulsatility generating centre [25]. All this will contribute to irregularity in the 
hormonal pattern of LH. LH is in turn responsible for the hyperplasia of the theca 
cells of the ovary which represents the anatomopathological substrate that supports 
hyperandrogenism.
Parallel to the hyperactivity of the LH-theca ovarian axis, there is a hypo-func-
tionality of the FSH-ovarian granulosa axis: in fact here is a constantly uniform FSH 
concentration, settled at values approximately 30% lower than the reference values 
[26]. The relative decrease of FSH levels my enhance a defective folliculogenesis 
that lead to maturation of follicles at the antral phase. Another factor influencing 
anovulation is the hyperandrogenic state and in particular the high concentration of 
androgens in the follicular microenvironment (Figure 2).
Two other important mechanisms of action of insulin are responsible for 
hyperandrogenaemia:
1. The inhibition of the hepatic synthesis of SHBG (sex hormone-binding globu-
lin), which determines a greater bioavailability of free oestrogens and andro-
gens [27].
2. The inhibition of hepatic production of IGFBP-1 (insulin-like growth factor-
binding protein-1) which increases the circulating levels of IGF-1 and its activ-
ity [28, 29]. Among the various actions, IGF-1 also appears to stimulate the 
activity of the enzyme 5α-reductase, responsible for converting testosterone 
into dihydrotestosterone, its active metabolite.
The concentration of insulin-like growth factor-binding protein-1 (IGFBP-1) is 
directly correlated to the degree of obesity, in fact overweight reduces its concentra-
tions even in non-PCOS women. As a result, obesity also plays an essential role in 
the pathogenesis of hyperandrogenism in PCOS, as BMI is the main determinant of 
IGFBP-1 Levels [29].
There is evidence that a vitamin D deficiency could be involved in the genesis 
of insulin resistance and metabolic syndrome in PCOS and would also play a role in 
determining the hormonal status of PCOS patients [30, 31].
Figure 2. 
Insulin action on the theca cell steroidogenesis [7].
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5. Clinical evaluation: Diagnostic criteria for PCOS in adult women
The prevalence of PCOS varies according to the diagnostic criteria used which 
usually include extension of hirsutism, level of circulating androgens, degree of 
irregularity of the menstruation and ultrasound morphology of the ovary.
Patients suffering from PCOS most frequently complain of:
1. Menstrual irregularities: usually associated with anovulation which is the cause 
of oligomenorrhoea (less than nine menstrual cycles per year; cycles of average 
duration exceeding 36–40 days). Anovulation in 30% of cases is accompanied 
by secondary amenorrhoea (no menstrual periods for three or more consecu-
tive months) which occurs after a period of variable oligomenorrhoea.
2. Hyperandrogenism. The most characteristic clinical presentations are hirsut-
ism and acne. Total testosterone is the best to reflect the androgenic status as 
the free testosterone level may not be very accurate. Total testosterone can be 
measured on any day of the menstrual cycle [32]. Other laboratory investiga-
tions that can be made are:
• Free androgen index (FAI) is the ratio between total testosterone and SHBG.
• Androstenedione is the direct precursor of testosterone, produced by the 
ovaries, adrenals and peripheral tissues. In women with PCOS, androstene-
dione levels can be increased even when the total testosterone is normal [33].
• DHEA-S is almost exclusively of adrenal origin and is increased in 
about 20–30% of PCOS patients. Hyperandrogenaemia, therefore, 
is predominantly of ovarian origin and supported by the increased 
activity of the P450c17 enzyme complex in thecal cells, which has two 
activities, 17α-hydroxylase, which converts progesterone to 17-OH-P, 
and 17–20 lyase, which transforms the latter into androstenedione 
(Figure 2). Androstenedione will then be converted into testosterone 
by 17β-hydroxysteroid dehydrogenase. In particular, the activity of 
17α-hydroxylase is increased. Furthermore, it appears to be an adrenal 
contribution to hyperandrogenaemia, again due to the excessive activation 
of the same microsomal enzyme P450c17, predominantly in the activity of 
17–20 lyase, although a hyper-responsiveness to ACTH is not to be excluded. 
Insulin is able to directly stimulate the enzymatic activity of P450c17, 
both at the adrenal and ovarian level [34]. A recent study has shown that 
androstenedione and total testosterone level helps to better assess the risk of 
developing metabolic syndrome in women with PCOS [33].
Figure 3. 
Ultrasound imaging of polycystic ovaries [35].
Polycystic Ovarian Syndrome
8
3. Polycystic ovary morphology: according to the Rotterdam criteria, the ovaries 
are defined as “polycystic” at least 1 ovary showing 12 or more follicles with 
average diameter 2–9 mm, regardless of their disposition, and/or a total ovar-
ian volume >10 ml3, examined with a transvaginal probe, and the evaluation 
must be carried out both in longitudinal and transverse scanning plane. It is 
sufficient that only one ovary has these characters, if evaluated in the follicular 
phase and in the absence of any hormonal treatment. Peripheral distribution 
of the follicles and hypertrophy of the ovarian stroma may be present but are 
not necessary for diagnosis (Figure 3).
6. Therapeutic approach
Therapeutic choices will be based on the type and extent of the disorders and if 
there is a desire for pregnancy.
The goals of the therapeutic action are:
• Improvement in menstrual cycles
• Reduce circulating androgens and signs of hyperandrogenism
• Reduce insulin resistance and prevent metabolic complications and decrease 
cardiovascular risk
• Try to achieve the ideal weight
• Treatment of infertility and improving the response to ovulation induction 
therapies
• Endometrial protection to prevent endometrial carcinoma
The therapeutic options available for PCOS are represented by lifestyle changes 
and the use of oral contraceptives, androgen receptor antagonists and insulin-
sensitizing drugs such as metformin and inositol-based supplements.
The first therapeutic approach in women with PCOS must be represented by 
lifestyle changes, by nutrition and in the presence of obesity or overweight by 
weight loss. In addition to an improvement in the metabolic comorbidities associ-
ated with obesity, weight loss reduces hyperinsulinaemia and increases insulin 
sensitivity, leading also to a decrease in LH and androgen levels.
Palomba et al. demonstrated in two cohorts of patients followed for 24 weeks, 
one of which was subjected to a regular exercise programme while the other 
to hypocaloric hyperproteic diet, in both cases there was a decrease in insulin 
resistance and improvement in menstrual cycles, fertility, SHBG and androgen 
levels [36].
Improvements of ovulation were found after weight loss in the PCOS obese patient 
as weight reduction could play the most significant role in restoring ovulation [37].
6.1 The use of combined oral contraceptive (COC) pill
This treatment produces regular menstrual cycles, decreases the risk of 
endometrial hyperplasia and improves acne and hirsutism. The treatment with 
COC pill represents therefore the therapy of first choice for the treatment of 
hyperandrogenism.
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COC treatment increases the hepatic synthesis of SHBG, reducing the propor-
tion of free and therefore metabolically active testosterone. Among the progesto-
gens that can be used in various associations, those with anti-androgenic activity 
are preferred, such as cyproterone acetate (which acts by preventing the binding of 
androgens to their cellular receptors) and drospirenone (which is a progestin with 
an anti-androgenic and anti-mineralocorticoid action).
6.2 Insulin-sensitizing treatment
The rationale of the use of insulin sensitizers in PCOS derives from the fact 
that 45–65% of PCOS patients have insulin resistance and compensatory hyper-
insulinaemia [38] which alter the steroidogenesis of the ovary and follicular 
maturation [39].
The classic insulin-sensitizing treatment is metformin, a biguanide traditionally 
used in the treatment of people with type 2 diabetes. Metformin acts by increasing 
the uptake and utilization of glucose at the level of skeletal muscle and adipose tis-
sue by reducing the insulin resistance and decreasing hepatic gluconeogenesis; it is 
also able to reduce intestinal glucose absorption and lipolysis, causing the reduction 
of substrates for gluconeogenesis.
Metformin has a significant effect on the reduction in circulating androgen 
levels, weight loss and regularization of menstrual cycles and ovulatory cycles [40].
Metformin action on androgens and the mechanisms by which metformin acts 
on hyperandrogenaemia are:
• Reduced production of androgens in the ovaries [41] and adrenals [42].
• Reduced pituitary secretion of LH [43].
• Increased SHBG liver production [44].
6.3 Inositol
It exerts an important control over glucose homeostasis, and when incorporated 
into phosphoglycans, it functions as an intracellular mediator of the action of 
insulin.
Inositol improves insulin sensitivity and ovulation rate, decreasing the testoster-
one concentration, blood pressure and plasma triglyceride concentrations [45].
The insulin-sensitizing action of inositol is the myo-inositol and the D-chiro-
inositol. The conversion of myo-inositol into D-chiro-inositol by the epimerase is 
dependent on insulin, so the liver and muscle (the insulin-sensitive tissues) are 
those in which the greatest conversion occurs. They are both chemical mediators 
of insulin. The activation of phospholipids containing myo-inositol by insulin 
causes an increase in the permeability of the cell membrane to glucose with con-
sequent increase in its internalization and availability for use. D-chiro-inositol, on 
the other hand, may allow the intracellular accumulation of glucose in the form 
of glycogen. The result of the action of both is however the increase in insulin 
sensitivity with consequent reduction in the circulating levels of insulin [46].
7. Conclusion
PCOS is a widespread pathology that affects multiple aspects of the general 
health of women, with long-term effects that go well beyond the reproductive age.
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The term “polycystic ovary syndrome” does not completely reflect the complex-
ity of this syndrome which manifests a wide spectrum of clinical manifestations 
and comorbidity and important metabolic implications. PCOS patients showed an 
increase risk of developing type 2 diabetes mellitus, dyslipidaemia, endometrial 
cancer and cardiovascular diseases.
The main features of PCOS are hyperandrogenism, oligomenorrhoea and 
ultrasound morphology of the ovary.
PCOS is also associated with reduced fibrinolytic activity due to increased levels 
of inhibitor of the plasminogen activator (PAI-I), independently of body mass 
index, as it is also found in thin women suffering from this syndrome and appears 
to correlate with the risk of abortion [47].
Atypical endometrial hyperplasia, whose incidence is increased, seems to be due 
both to chronic exposure to high levels of oestrogens, not balanced by an adequate 
amount of progesterone (due to chronic anovulation).
Patients with PCOS also have reproductive alterations, evidence of insulin resis-
tance, anxiety and depression. If pregnant, these women have a significant increase 
in the risk of developing gestational complications like miscarriage, gestational 
diabetes, pre-eclampsia and preterm birth [48].
The mechanisms that could determine insulin resistance (IR) areexcessive serine 
phosphorylation of the insulin receptor subunit, mutations of the insulin receptor 
gene, depletion of intracellular adenosine, post-receptor defect of glucose transport 
and impaired insulin clearance in the peripheral tissues.
The PCOS Consensus Workshop Group in Rotterdam in which the diagnostic 
criteria were reviewed, allowing a broader spectrum of PCOS phenotypes to be 
included in the diagnosis defining PCOS as the presence of at least two of the fol-
lowing criteria after excluding other causes of hyperandrogenism [49], is as follows:
• Oligo-anovulation
• Hyperandrogenism with clinical or biochemical signs
• Polycystic ovary appearance on ultrasound examination
The therapeutic choices will be based on the type and extent of the disorders and 
if there is a desire for pregnancy.
The goals of the therapeutic action are to reduce circulating androgens and signs 
of hyperandrogenism, reduce insulin resistance and prevent metabolic complica-
tions and decrease cardiovascular risk.
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